ArgenTAG
High-resolution single-cell long read seq | New York
New York, United States · Founded 2021
- Headquarters
- New York, New York
- Founded
- 2021
- Website
- argentag.com
- Last Round
- SeedJul 2022
- Rounds
- 2
About
ArgenTag is a New York-based biotechnology company developing instrument-free, high-resolution single-cell RNA library kits for long-read sequencing. Its end-to-end platform is compatible with PacBio and Oxford Nanopore Technologies, enabling research institutions and biotech companies to achieve single-cell, long-read isoform sequencing on the benchtop. ArgenTag serves academic labs and industry partners tackling cancer, rare diseases, stem cell research, and infectious disease through complete biological clarity at single-cell resolution.
Summary
ArgenTAG is a Biotech company based in New York, United States, founded in 2021. Its most recent funding was a Seed round in Jul 2022. Investors include IndieBio, Draper University and BioTools Innovator.
Tech & App Stack
2 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jul 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.